Researchers from the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have identified a critical quality attribute (CQA) that potentially allows the development of a rapid and sensitive process analytical technology for sterility. Specifically, this technology enables the detection of early-stage microbial contamination in human cell therapy products (CTPs). Cell therapy represents one of the most advanced biotechnology revolutions in medicine, with strong potential to repair damaged tissues and treat a range of conditions such as degenerative diseases and cancer. It works by delivering living cells…
